Laboratory of targeted gene mapping for predictive oncological diagnostics of Czech Center Digital Genomics (Q11526): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
||
| Property / financed by | |||
| Property / financed by: Directorate-General for Regional and Urban Policy / rank | |||
Revision as of 15:53, 28 October 2020
Project Q11526 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Laboratory of targeted gene mapping for predictive oncological diagnostics of Czech Center Digital Genomics |
Project Q11526 in Czech Republic |
Statements
25,300,500.0 Czech koruna
0 references
50,601,000.0 Czech koruna
0 references
50 percent
0 references
31 March 2020
0 references
Institute of Applied Biotechnologies a.s.
0 references
50°5'1.93"N, 14°30'28.48"E
0 references
10800
0 references
10800
0 references
Záměrem projektu TGM je vytvoření nového pracoviště pro cílené mapování lidského genomu, které bude sloužit k kolaborativnímu vývoji a klinickému výzkumu nových produktů pro stanovení ranných stádií rakoviny s využitím cirkulujících buněk z krve. Plánujeme zásadním způsobem přispět k rozvoji Theranostiky v ČR, tedy terapie založené na diagnostice, která vede k personalizaci zdravotní péče, zvýšení efektivity a cílené terapie a výrazně snižuje léčebné náklady. a. (Czech)
0 references
The aim of the TGM project is to create a new workplace for targeted mapping of the human genome, which will serve for collaborative development and clinical research of new products for the determination of early stages of cancer using circulating cells from blood. We plan to make a major contribution to the development of Theranostka in the Czech Republic, i.e. diagnostic therapy, which leads to personalisation of health care, increased efficiency and targeted therapy and significantly reduces medical costs. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_093/0012409
0 references